Skip to main content
. 2024 Apr 24;19(4):e0300544. doi: 10.1371/journal.pone.0300544

Fig 8. Tesofensine prolongs body weight loss produced by serotonin precursor 5-HTP/CB on the chow control diet in rats.

Fig 8

A. Change in body weight (g) relative to pretreatment day 0. Tesofensine1 and tesofensine2 refer to doses of 1 and 2 mg/kg administered subcutaneously, respectively. 5-HTP/CB refers to doses of 31 and 75 mg/kg administered intraperitoneally. Note that the triple combination of tesofensine, 5-HTP, and CB led to significantly greater weight loss than any other group and did not show weight loss tolerance as seen in 5-HTP/CB group (see horizontal line at days 7–15). B. Changes in food intake for the groups shown in panel “A.” Note that 5-HTP/CB, tesofensine1, and 2 + 5-HTP/CB groups exhibited anorexigenic tolerance, as evidenced by their increased food intake from day 7 to 15. Data are presented as mean ± SEM. n = number of rats. Repeated Measures ANOVA (A-B). $ p < 0.05 tesofensine1 compared with tesofensine1 + 5-HTP/CB, and 5-HTP/CB groups. % p < 0.05 tesofensine2 compared to tesofensine2 + 5-HTP/CB, and 5-HTP/CB groups. * p < 0.05 compared with the control group.